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ABSTRACT
Bile acid malabsorption is a common cause of chronic
diarrhoea in people, however it has never previously
been investigated in dogs, despite clinical suspicion of
its existence. The goal of this study was to assess the
feasibility of measuring serum 7α-hydroxy-4-
cholesten-3-one (C4) in dogs, as a potential marker of
bile acid malabsorption, and to see whether this is
related to clinical disease severity or the presence of
hypocobalaminaemia. Serum C4 concentration was
measured in 20 clinically healthy control dogs and 17
dogs with chronic diarrhoea. Three of the 17 affected
dogs (17.6 per cent) had a C4 concentration
significantly above the range of clinically healthy dogs;
these dogs were all poorly responsive to conventional
therapy. These results suggest that bile acid
malabsorption may be a clinically relevant disorder in
dogs with chronic diarrhoea and serum C4 may be a
useful tool to investigate this further.
INTRODUCTION
Malabsorption of bile acids, as a cause of
diarrhoea, has been recognised in human
medicine for some time (Fromm and
Malavolti 1986). It is known that in patients
who have undergone terminal ileal resection
or have reduced ileal function due to
disease, bile acid absorption is reduced,
leading to the presence of bile acids in the
colon. Here they cause chloride and water
secretion and increase colonic motility,
resulting in diarrhoea, so-called secondary or
type 1 bile acid malabsorption (Johnston and
others 2011). The prevalence of bile acid
malabsorption is between 10 and 35.3 per
cent in people with chronic diarrhoea,
depending on the serum C4 cut-off used
(Wedlake and others 2009, Slattery and
others 2015).
Various methods have been described to
diagnose bile acid malabsorption in humans
(Vijayvargiya and others 2013). Until
recently, the most commonly utilised was the
75selenium homotaurocholic acid test
(SeHCAT); this uses a synthetic radioactive
bile acid, the retention time of which can be
measured using a gamma camera (Balzer
1995). A downstream product of one of the
major enzymes in the bile acid synthesis
pathway is 7α-hydroxy-4-cholesten-3-one (C4)
and, in people, blood concentrations show
good correlation with the rate of bile acid
synthesis (Galman and others 2003). Bile
acid synthesis is increased in patients with
bile acid malabsorption as they have
increased faecal bile acid losses and there-
fore less recycling of bile acids through the
process of enterohepatic recirculation
(Camilleri and others 2009). Multiple studies
have now shown good correlation between
serum C4 and SeHCAT in the diagnosis of
bile acid malabsorption with a sensitivity of
87–90 per cent and speciﬁcity of 79–86 per
cent compared with SeHCAT (Eusufzai and
others 1993, Brydon and others 1996, Fan
and Sellin 2009, Johnston and others 2011,
Grutzner and others 2014). C4 has signiﬁ-
cant advantages over other methods as it
only requires one blood sample, avoids radi-
ation risks and does not require immediate
access to expensive equipment. To the
authors’ knowledge, bile acid malabsorption
has not been documented in dogs or cats,
nor has SeHCAT been described. However,
the authors have anecdotal evidence of a
clinical response of patients with refractory
chronic enteropathies to the bile acid seques-
trant cholestyramine, which is a commonly
used drug for this condition in people
(Pattni and Walters 2009). An improved
ability to recognise and diagnose cases of
bile acid malabsorption would have signiﬁ-
cant clinical beneﬁt as these cases may
require speciﬁc treatments for this condition
and may be less likely to respond to
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conventional therapy. The purpose of this study was to
document serum C4 concentration in a group of dogs
with chronic diarrhoea and to compare this to a group
of clinically healthy control dogs. The authors hypothe-
sised that approximately 10 per cent of dogs with
chronic diarrhoea would be affected by bile acid malab-
sorption, indicated by an elevated serum C4 concentra-
tion; this ﬁgure was based on the reported prevalence in
people with chronic enteropathies (Wedlake and others
2009). They also hypothesised that dogs with hypocoba-
laminaemia may be more likely to have elevated serum
C4 as cobalamin and bile acids are absorbed in a similar
region of the small intestine. Lastly, serum C4 concentra-
tion was compared with the canine chronic enteropathy
activity index in order to determine whether bile acid
malabsorption was related to clinical disease severity.
MATERIALS AND METHODS
Clinical cases were identiﬁed by searching the clinical
pathology database at the Queen’s Veterinary School
Hospital, from January 2012 to March 2015, to identify
patients in which serum cobalamin had been measured.
The clinical records of these dogs were then reviewed
and cases were included if they had undergone investi-
gation of chronic diarrhoea and an adequate volume of
stored, frozen serum was available in the sample archive.
Diagnostic investigations were performed as appropri-
ate to each case, but typically included some combination
of routine haematology and biochemistry, basal cortisol,
faecal analysis, canine trypsin-like immunoreactivity,
folate, cobalamin, abdominal ultrasound and gastrointes-
tinal biopsies (most commonly gastric, duodenal, ileal
and colonic biopsies). The ﬁnal diagnosis was recorded
for each case. Canine chronic enteropathy activity index
scores were estimated and classiﬁed according to previ-
ously published guidance (Allenspach and others 2007)
either at the time the case was investigated or retrospect-
ively based on clinical notes. This involved severity
scoring, on a scale of 0–3, 9 parameters: attitude/activity,
appetite, frequency of vomiting, stool consistency, stool
frequency, severity of weight loss, serum albumin levels,
presence of ascites/oedema and severity of pruritus.
Cases are then classiﬁed into insigniﬁcant disease (score
0–3), mild disease (4–5), moderate disease (6–8), severe
disease (9–11) or very severe disease (12–27).
Controls were clinically healthy dogs identiﬁed by
searching the clinical records database, over the same
time period as clinical cases, for cases in which blood
had been collected as part of routine pre-anaesthetic
screening, most commonly prior to orthopaedic surgery.
Dogs were only included if they had no history of gastro-
intestinal signs, an unremarkable haematology and bio-
chemistry, and an adequate volume of stored, frozen
serum was available in the sample archive. Dogs were
age matched to the clinical cases.
All blood samples were taken following an overnight
fast into serum gel tubes; these were separated after
clotting and the samples frozen at –80°C for storage, as
is standard practice for all residual samples from clinical
cases at this hospital. When required, the samples were
shipped from the laboratory on dry ice for batch
analysis.
Serum C4 was measured using liquid chromatography-
mass spectrometry (LC-MS/MS) (see online supplemen-
tary appendix 1). Brieﬂy, to 250 μl of the sample was
added 250 μl of deuterated internal standard working
solution (containing 125 nmol/l of C4-d7 in aceto-
nitrile) followed by a further 500 μl of ice-cold aceto-
nitrile in a tube. Samples were then vortexed for
30 seconds followed by centrifugation for 10 minutes at
16,000g. The supernatant of this is transferred to a glass
high-performance liquid chromatography injection
phial and 50 μl in injected onto the LC-MS/MS system.
For LC-MS/MS, an Aria Transcend TLX-II system and
TSQ Vantage were utilised (both ThermoFisher
Scientiﬁc, San Jose, USA). Isocratic chromatography
with a 5:95 (V/V) mixture of (A) 0.1 per cent (V/V)
aqueous formic acid and (B) 0.1 per cent (V/V) formic
acid in methanol was performed using an Acentis fused-
core C18 analytical column (150×4.6 mm, particle size
2.7 µm, Sigma-Aldrich). Flow rate was 0.8 ml/minute
with the column being maintained at 40°C using a
HotPocket (ThermoFisher Scientiﬁc). LC-MS/MS was
carried out in selected reaction monitoring mode (two
m/z transitions) using positive atmospheric-pressure
chemical ionisation.
Statistical analysis was performed using commercially
available software (SPSS, IBM). A Mann-Whitney U test
was used to compare the age and C4 measurements of
the two groups. A Spearman’s rank correlation test was
used to assess the relationship between C4 concentra-
tion, serum cobalamin and clinical activity index. A
receiver operating characteristic (ROC) curve was pro-
duced in order to deﬁne the sensitivity and speciﬁcity of
serum C4 concentration for presumptive diagnosis of
bile acid malabsorption using different cut-off values.
RESULTS
Serum cobalamin measurements were available for 74
dogs over the study period. A total of 57 cases were
excluded due to insufﬁcient stored serum (49 cases) or
inappropriate clinical history (8 cases), leaving 17 cases
for analysis. Serum C4 measurement was consequently
available for 17 dogs with chronic diarrhoea and 20
control dogs.
Clinical cases had an age range from 1.5 to 12 years
(median 8 years), control dogs had an age range from
1.1 to 12 years (median 5.5 years) and there was no sig-
niﬁcant difference between the ages of these groups
(P=0.170). The breeds of the dogs in both groups are
listed in Table 1.
The ﬁnal diagnosis in the cases with chronic diarrhoea
included idiopathic inﬂammatory bowel disease (11
cases), diet-responsive enteropathy (2 cases),
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antibiotic-responsive enteropathy (2 cases), exocrine
pancreatic insufﬁciency (1 case) and a suspected corona
virus infection (1 case). The diagnosis of inﬂammatory
bowel disease was based on histopathological examin-
ation of gastrointestinal biopsies, most commonly
gastric, duodenal and ileal biopsies. The diagnosis of
corona virus was based on faecal PCR testing and even-
tual resolution of clinical signs with symptomatic
treatment.
Control dogs had a serum C4 range from 15.1 to
180.1 nmol/l (median 80.9 nmol/l), dogs with chronic
diarrhoea had a serum C4 range from 21.3 to
518.6 nmol/l (median 59.9 nmol/l) and there was no
signiﬁcant difference in the C4 concentration between
these two groups (P=0.8). Figure 1 shows a boxplot of
the serum C4 concentration in the two groups. Serum
cobalamin and canine chronic enteropathy activity
index were available for all clinical cases. Cobalamin
concentration ranged from 100 to 834 pg/ml (median
338 pg/ml), and canine chronic enteropathy activity
index scores ranged from 4 to 15 (median 7). When
assessing the relationship between serum C4 concentra-
tion and serum cobalamin, no statistically signiﬁcant
relationship was identiﬁed (P=0.6, correlation
TABLE 1: Breed, C4, serum cobalamin concentration and clinical features of the control and clinical cases
Breed Age (years)
Cobalamin (pg/ml)
Normal >200 C4 (nmol/l)
Canine chronic
enteropathy activity index Diagnosis
Clinically healthy dogs
Border terrier 2.7 N/A 15.1 N/A N/A
Hungarian vizsla 1.7 N/A 22.7 N/A N/A
Labrador retriever 5.0 N/A 29.9 N/A N/A
Lurcher 3.0 N/A 35.9 N/A N/A
Golden retriever 2.0 N/A 40.0 N/A N/A
Cross breed 7.0 N/A 41.1 N/A N/A
Cocker spaniel 2.5 N/A 8.9 N/A N/A
Labrador cross 8.2 N/A 58.8 N/A N/A
Yorkshire terrier 1.3 N/A 74.8 N/A N/A
Labrador retriever 6.0 N/A 77.2 N/A N/A
German shepherd dog 9.0 N/A 84.6 N/A N/A
Rottweiler 8.0 N/A 100.4 N/A N/A
Schnauzer 8.0 N/A 105.0 N/A N/A
Japanese spitz 4.5 N/A 105.3 N/A N/A
Labrador retriever 3.0 N/A 108.2 N/A N/A
Labrador retriever 10.0 N/A 143.0 N/A N/A
Labrador retriever 12.0 N/A 146.5 N/A N/A
Shiba inu 9.0 N/A 164.0 N/A N/A
Mastiff 1.1 N/A 176.5 N/A N/A
Boxer 9.5 N/A 180.2 N/A N/A
Group median 5.5 N/A 80.9
Clinical cases
Greyhound 8.0 523 21.3 6 IBD
Tibetan terrier 10.0 338 25.1 13 IBD
Miniature poodle 4.0 556 25.8 8 IBD
Wheaten terrier 7.0 199 26.2 15 IBD
Greyhound 10.0 121 34.2 7 IBD
Cocker spaniel 8.0 834 37.1 5 ARE
German shepherd dog 4.25 217 40.1 6 ARE
Airedale terrier 5.0 338 43.9 5 DRE
German shepherd dog 2.9 443 59.9 5 EPI
Staffordshire bull ter. 9.5 162 119.8 12 IBD
Miniature schnauzer 9.0 272 120.0 11 IBD
Rottweiler 1.5 558 129.3 5 IBD
Rottweiler 8.8 190 178.9 4 DRE
Shiba inu 12.0 353 194.3 7 Coronavirus
Jack Russell ter. cross 5.0 310 362.7 10 IBD
Border collie 6.0 100 438.0 9 IBD
Border terrier 11.0 550 518.6 6 IBD
Group median 8.0 338 59.9 7
ARE, antibiotic-responsive enteropathy; DRE, diet-responsive enteropathy; EPI, exocrine pancreatic insufficiency; IBD, inflammatory bowel
disease; N/A, not applicable
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coefﬁcient=−0.11). There was also no statistically signiﬁ-
cant relationship between canine chronic enteropathy
activity index and serum C4 (P=0.6, correlation coefﬁ-
cient=−0.04).
A cut-off value for serum C4 concentration of
187.2 nmol/l on the ROC curve resulted in a speciﬁcity
of 100 per cent (95 per cent CI 81.5 to 100 per cent)
and a sensitivity of 25 per cent (95 per cent CI 5.3 to
48.6 per cent) for presumptive diagnosis of bile acid
malabsorption in this group of dogs (Fig 2), with a posi-
tive predictive value (PPV) of 100 per cent (95 per cent
CI 31 to 100 per cent) and a negative predictive value
(NPV) of 59 per cent (95 per cent CI 41 to 75 per
cent). If 187.2 nmol/l is set as the upper limit of
normal, then three (17.6 per cent; 95 per cent CI 6.2 to
41.0 per cent) of the clinical cases with chronic diar-
rhoea had a serum C4 concentration signiﬁcantly above
this (at least twice this upper limit). The greatest serum
C4 concentration (518.6 nmol/l) was observed in an
11-year-old, neutered male border terrier. This dog was
diagnosed with suspected inﬂammatory bowel disease,
which was partially, although never fully, responsive to
dietary modiﬁcation and immunosuppressive medication
(prednisolone and azathioprine). This dog had a serum
cobalamin concentration within the reference range
(550 pg/ml). The second case with a marked serum C4
elevation (438.0 nmol/l) was a 6-year-old, neutered male
border collie. This dog had a complex medical history
of previous primary hypoparathyroidism and more
recent inﬂammatory bowel disease. Concerns regarding
the effect of prednisolone on serum calcium concentra-
tions prevented use of this drug, and so the dog was pri-
marily managed with chlorambucil and dietary
modiﬁcation; however, his diarrhoea was also poorly
responsive to this treatment. Interestingly, at a later time
this case was trialled on cholestyramine and showed an
improvement in faecal consistency; however, a further
dietary modiﬁcation was made at the same time, making
the response difﬁcult to interpret. This dog also had sig-
niﬁcant hypocobalaminaemia (100 pg/ml), suggesting
marked distal small intestinal disease. The third case
(serum C4 concentration 362.7 nmol/l) was a 5-year-old,
neutered female Jack Russell terrier cross. This dog pre-
sented for investigation of chronic diarrhoea and panhy-
poproteinaemia and was diagnosed with idiopathic
inﬂammatory bowel disease. She was treated with pred-
nisolone, chlorambucil and metronidazole, along with
dietary modiﬁcation. This resulted in an improvement
of clinical signs and normalisation of serum proteins;
however, the diarrhoea persisted intermittently.
Malabsorption of bile acids may offer a potential explan-
ation for the limited response of the diarrhoea to
therapy; however, no therapeutic trials were ever per-
formed to conﬁrm this. This dog had a serum cobala-
min concentration at the lower end of the reference
range (310 pg/ml).
The remaining 14 clinical cases were treated with a
variety of medications, depending on diagnosis and had a
range of outcomes. The two cases of antibiotic-responsive
enteropathy, two cases of diet-responsive enteropathy, two
case of suspected enteric coronavirus and two case of exo-
crine pancreatic insufﬁciency were all treated appropri-
ately for those conditions with an excellent response. The
eight cases with idiopathic inﬂammatory bowel disease
were treated with a number of medications, including
prednisolone alone (ﬁve cases), prednisolone with
azathioprine (one case), prednisolone with chlorambucil
(one case) and prednisolone with ciclosporin (one case).
Seven of these eight cases responded well to treatment
with good long-term control of clinical signs; one case
deteriorated despite therapy resulting in eventual euthan-
asia. This dog had a low serum C4 level (25.12 nmol/l).
Post hoc power analysis was performed and showed
that two groups of 76 cases would be required to detect
a statistically signiﬁcant difference (α=0.05 and power,
1−β=0.80) if similar results were obtained in the two
groups.
DISCUSSION
In the small group of dogs examined in this study, there
was no overall difference in the serum C4 concentration
between dogs with and without chronic diarrhoea. In
people, the reference range for serum C4 is 14.3–
60.7 nmol/l. However, 12 (60 per cent) of the control
dogs in this study had a concentration outside that refer-
ence range, suggesting that the reference range in dogs
may be higher. The ROC analysis suggests that a cut-off
value of 187.2 nmol/l would give a high speciﬁcity for
the suspected diagnosis of bile acid malabsorption. The
sensitivity in this study was low; largely due to the small
sample size. This is likely to be improved if only dogs
with a poor response to conventional therapy were
tested, in which the suspicion of bile acid malabsorption
might be higher. The high speciﬁcity and high PPV
suggest that this test would be most useful as a screening
test to increase clinical suspicion of bile acid
FIG 1: A box plot demonstrating serum C4 concentrations in
clinically healthy dogs and dogs with chronic diarrhoea
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malabsorption in dogs with chronic diarrhoea; however,
false negative results are likely and a normal serum C4
concentration does not exclude this disease. Larger
studies are needed to reﬁne the reference range for
dogs, with the aim of improving test sensitivity and NPV.
This test is relatively inexpensive to perform (approxi-
mately £30 per sample), but is currently only available
through a small number of specialist human hospital
labs. However, it is being run more commonly in people
and so it is likely to become more widely available in the
future. The reliability of the test is also excellent, with a
low coefﬁcient of variation both intra-assay and inter-
assay (see online supplementary appendix 1).
While the small numbers in this study make deﬁnite
conclusions difﬁcult, elevated serum C4 was identiﬁed
in three dogs with chronic diarrhoea and, interestingly,
all of these cases had clinical disease with a limited
response to traditional therapy. Ideally these cases would
have undergone SeHCAT in order to increase the clin-
ical suspicion, but the authors’ results suggest that bile
acid malabsorption may well be a factor in some cases of
chronic enteropathy. Measuring serum C4 could there-
fore be useful in cases of chronic enteropathy that fail to
respond to standard treatments.
We hypothesised that there may be a relationship
between an elevated serum C4 concentration and hypo-
cobalaminaemia, based on the knowledge that both
abnormalities may be associated with distal small intes-
tinal disease (Berghoff and others 2013); however, there
was no evidence of such a relationship. One of the cases
with particularly high serum C4 concentration did have
a very low serum cobalamin, suggesting that signiﬁcant
distal small intestinal pathology may lead to both these
changes in some cases. There was also no evidence of an
association between the clinical severity of the disease, as
measured by the clinical activity index, and serum C4
concentration. However, the numbers were very small in
this pilot study, which was signiﬁcantly underpowered to
ﬁnd any associations, as demonstrated by the post hoc
power estimations.
It is currently unclear, in both dogs and people, why
bile acid malabsorption occurs. Proposed mechanisms
include a defective ileal bile acid transport system, a
reduced contact time of bile acids in the ileum due to
increased motility and an increased bile acid pool size
due to disordered negative feedback mechanisms on
bile acid synthesis (Pattni and Walters 2009).
A number of potential treatments exist for bile acid
malabsorption if it is identiﬁed or suspected.
Glucocorticoids have been shown to upregulate the bile
acid transporter apical sodium linked bile acid trans-
porter (ASBT) in people (Johnston and others 2011),
which may explain the positive response to these medica-
tions in many cases. Glucocorticoids form the mainstay of
immunosuppressive treatment in inﬂammatory intestinal
diseases and may be treating bile acid malabsorption as a
useful side effect of therapy. The bile acid sequestrant
cholestyramine is the ﬁrst-line treatment in most people
with bile acid malabsorption and is effective in between
63 and 100 per cent of people in different studies
(Wilcox and others 2014). This has been used success-
fully in both dogs and cats; however, it is not licensed in
either of these species. An alternative sequestrant is cole-
sevelam, which has shown beneﬁt in patients who were
intolerant or unresponsive to cholestyramine (Beigel and
others 2014). However, to the authors’ knowledge, colese-
velam has not been used on canine patients. It is likely
that dietary management is also important in managing
these cases. Increasing dietary fat has been shown to
increase faecal bile acid secretion in people (Koga and
others 1984), and therefore, a low-fat diet is probably pre-
ferred (Westergaard 2007).
In addition to being underpowered, the retrospective
nature of this study did not allow a comparison of serum
C4 measurement to the gold standard of SeHCAT. It was
therefore not possible to conﬁrm that serum C4 eleva-
tions indicate malabsorption of bile acids. It is possible
that serum C4 was elevated by an alternative mechanism
in these patients. However, this pilot study suggests that
this is a worthwhile area to investigate further. Second,
accurate clinical follow-up on cases was restricted and
cases with abnormal C4 concentrations were not able to
be assessed for response to speciﬁc therapy. Lastly, it
would have been interesting to measure serum cobala-
min for the control cases as well as the clinical cases;
however, as the samples came from residual archived
blood, insufﬁcient volumes were available to measure
both parameters.
In conclusion, this study suggests that C4 measure-
ment is feasible in dogs and may indicate the presence
FIG 2: A receiver operating characteristic (ROC) curve for
various cut-off levels of serum C4 concentration
demonstrating the sensitivity and specificity for the presumed
diagnosis of bile acid malabsorption
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of bile acid malabsorption in some cases. Assuming that
bile acid malabsorption occurs in cases with elevated
serum C4, 17.6 per cent (3/17; 95 per cent CI 6.2 to
41.0 per cent) of the dogs with chronic diarrhoea in this
study may have had bile acid malabsorption, similar to
what has been found in people. However, larger studies
are needed to deﬁne the true prevalence in dogs as the
prevalence in this study is speculative. While further
studies are needed to explore the clinical signiﬁcance,
clinicians should be aware of the potential for bile acid
malabsorption in cases that are poorly responsive to con-
ventional therapies.
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